Subject(s)
Carrier Proteins/metabolism , Hematopoietic Stem Cells/metabolism , Leukemia, Promyelocytic, Acute/metabolism , Nuclear Proteins/metabolism , Oncogene Proteins, Fusion/metabolism , Retinoic Acid Receptor alpha/metabolism , Retinoids/metabolism , Stem Cells/metabolism , Adult , Chromosomes, Human, Pair 15/metabolism , Chromosomes, Human, Pair 17/metabolism , DNA-Binding Proteins , Humans , Male , Transcription Factors , Translocation, Genetic/physiologyABSTRACT
Quantitative PCR (qPCR) for detection of fusion transcripts and overexpressed genes is a promising tool for following minimal residual disease (MRD) in patients with hematological malignancies. Its widespread clinical use has to some extent been hampered by differences in data analysis and presentation that complicate multicenter clinical trials. To address these issues, we designed a highly flexible MRD-reporting software program, in which data from various qPCR platforms can be imported, processed, and presented in a uniform manner to generate intuitively understandable reports. The software was tested in a two-step quality control (QC) study; the first step involved eight centers, whose previous experience with the software ranged from none to extensive. The participants received cDNA from consecutive samples from a BCR-ABL+ chronic myeloid leukemia (CML) patient and an acute myeloid leukemia (AML) patient with both CBFß-MYH11 and WT1 target genes, they conducted qPCR on their respective hardware platforms and generated a series of reports with pre-defined features. In step two, five centers used the software to report BCR-ABL+ MRD in a harmonized manner, applying their recently obtained CML international scale conversion factors. The QC study demonstrated that this MRD-reporting software is suitable for efficient handling of qPCR data, generation of MRD reports and harmonization of MRD data.
